Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders to neoadjuvant therapy. Des...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Francis W., Barker, Hilary R., Lipert, Barbara, Rothé, Françoise, Gebhart, Géraldine, Piccart-Gebhart, Martine J., Sotiriou, Christos, Jamieson, Stephen M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054312/
https://www.ncbi.nlm.nih.gov/pubmed/31839676
http://dx.doi.org/10.1038/s41416-019-0635-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054312/
https://www.ncbi.nlm.nih.gov/pubmed/31839676
http://dx.doi.org/10.1038/s41416-019-0635-y

Ejemplares similares